Skip to main content
Tech.euFundingExplorerBeta

Limula

Limula is building a smart automation solution for the production of the most complex, most expensive, but also most personalized cancer treatment ever invented.

Limula has raised €6.5M across 4 funding rounds from 9 investors. Based in Vaud, Switzerland; active in Healthtech. Data as of 28 Oct 2026.

Total raised
€6.5M
€6,496,442
Funding rounds
4
Investors
9
distinct backers
Active since
2022-10

Funding by year

EUR raised per year
Limula — funding by year — interactive chart.
Data table
Limula — funding by year
2022€0
2023€237k
2024€6.3M

Signals

High confidence
Raise-next likelihood11
base rate 44% for Seed
  • ▼ Past typical raise window
  • ▲ Up-round momentum
  • ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
  • ▼ No recent equity round (debt-only or quiet)

Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

4 rounds
DateStageAmountInvestors
—Other——View deal →
2024-05-21Seed€6.3MAngel Investors,Lichtsteiner Foundation,LifeX Ventures,Oxford Seed Fund,Verve Ventures,W.A. de Vigier Foundation+1 moreView deal →
2023-10-16Other€237kBioTools InnovatorView deal →
2022-10-11Other—Biopôle Start-up FundView deal →

Similar companies

same sector or country

Global coverage: FundingData